Marc Chamberlain

Prior to joining Pionyr, Marc Chamberlain was Medical Director at SystImmune, Inc where he developed protocols for novel multi-valent monoclonal antibodies for first in human early phase clinical trials. Before that, he served as Medical Director at Seattle Genetics following its acquisition of Cascadian Therapeutics, where he led clinical stage development of a novel HER2 tyrosine kinase inhibitor, tucatinib, through clinical proof of concept in HER2 positive metastatic breast cancer and subsequently helping to develop and execute a randomized Phase 2/3 global trial which resulted in an FDA approval. Before joining industry, Dr. Chamberlain was a professor and academic oncologist, where he had both extensive experience as a clinician (specializing in neuro-oncology) as well as serving as Principal Investigator on multiple trials, including cooperative group, pharma sponsored as well as investigator-initiated trials. Dr. Chamberlain received his M.D. from Columbia University, College of Physicians and Surgeons and completed residencies/fellowships in pediatrics, neurology and neuro-oncology at the University of California, Los Angeles and the University of California, San Francisco. He has authored more than 500 scientific publications in major journals.